These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 27925256)

  • 1. Pharmacokinetic drug-drug interactions of tyrosine kinase inhibitors: A focus on cytochrome P450, transporters, and acid suppression therapy.
    Gay C; Toulet D; Le Corre P
    Hematol Oncol; 2017 Sep; 35(3):259-280. PubMed ID: 27925256
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolism-related pharmacokinetic drug-drug interactions with tyrosine kinase inhibitors: current understanding, challenges and recommendations.
    Teo YL; Ho HK; Chan A
    Br J Clin Pharmacol; 2015 Feb; 79(2):241-53. PubMed ID: 25125025
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinically relevant drug interactions with multikinase inhibitors: a review.
    Hussaarts KGAM; Veerman GDM; Jansman FGA; van Gelder T; Mathijssen RHJ; van Leeuwen RWF
    Ther Adv Med Oncol; 2019; 11():1758835918818347. PubMed ID: 30643582
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Consequences of Hypoacidity Induced by Proton Pump Inhibitors - a Practical Approach.
    Rychlíčková J
    Klin Onkol; 2018; 31(6):409-413. PubMed ID: 31035765
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tyrosine Kinase Inhibitors and Proton Pump Inhibitors: An Evaluation of Treatment Options.
    van Leeuwen RWF; Jansman FGA; Hunfeld NG; Peric R; Reyners AKL; Imholz ALT; Brouwers JRBJ; Aerts JG; van Gelder T; Mathijssen RHJ
    Clin Pharmacokinet; 2017 Jul; 56(7):683-688. PubMed ID: 28101705
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug-drug interactions in patients receiving tyrosine kinase inhibitors.
    Keller KL; Franquiz MJ; Duffy AP; Trovato JA
    J Oncol Pharm Pract; 2018 Mar; 24(2):110-115. PubMed ID: 27941080
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Systematic Review of Gastric Acid-Reducing Agent-Mediated Drug-Drug Interactions with Orally Administered Medications.
    Patel D; Bertz R; Ren S; Boulton DW; Någård M
    Clin Pharmacokinet; 2020 Apr; 59(4):447-462. PubMed ID: 31788764
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic Polymorphism on the Pharmacokinetics and Pharmacodynamics of Platelet-derived Growth Factor Receptor (PDGFR) Kinase Inhibitors.
    Qian Y; Yu L; Zhang XH; Yuan ZQ; Zhao P; Sun LN; Wang YQ
    Curr Drug Metab; 2018; 19(14):1168-1181. PubMed ID: 29956623
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic optimisation in the treatment of gastro-oesophageal reflux disease.
    Hatlebakk JG; Berstad A
    Clin Pharmacokinet; 1996 Nov; 31(5):386-406. PubMed ID: 9118586
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Physicochemical properties of novel protein kinase inhibitors in relation to their substrate specificity for drug transporters.
    Da Silva CG; Honeywell RJ; Dekker H; Peters GJ
    Expert Opin Drug Metab Toxicol; 2015 May; 11(5):703-17. PubMed ID: 25633410
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enzyme- and transporter-mediated drug interactions with small molecule tyrosine kinase inhibitors.
    Shao J; Markowitz JS; Bei D; An G
    J Pharm Sci; 2014 Dec; 103(12):3810-3833. PubMed ID: 25308414
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug-drug Interactions of Angiotensin Converting Enzyme Inhibitors Mediated by Metabolizing Enzymes and Transporters.
    Sun P; Liu K
    Curr Drug Metab; 2018; 19(13):1119-1129. PubMed ID: 30062958
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detection and prevention of drug-drug interactions in the hospitalized elderly: utility of new cytochrome p450-based software.
    Zakrzewski-Jakubiak H; Doan J; Lamoureux P; Singh D; Turgeon J; Tannenbaum C
    Am J Geriatr Pharmacother; 2011 Dec; 9(6):461-70. PubMed ID: 22019006
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel Bruton's tyrosine kinase inhibitor remibrutinib: Assessment of drug-drug interaction potential as a perpetrator of cytochrome P450 enzymes and drug transporters and the impact of covalent binding on possible drug interactions.
    Schiller H; Huth F; Schuhler C; Drollmann A; Kaul M; Woessner R; Shah B; Weis W; End P
    Eur J Pharm Sci; 2022 May; 172():106155. PubMed ID: 35247543
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic Aspects of Vascular Endothelial Growth Factor Tyrosine Kinase Inhibitors.
    Wulkersdorfer B; Zeitlinger M; Schmid M
    Clin Pharmacokinet; 2016 Jan; 55(1):47-77. PubMed ID: 26201307
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma concentrations of tyrosine kinase inhibitors imatinib, erlotinib, and sunitinib in routine clinical outpatient cancer care.
    Lankheet NA; Knapen LM; Schellens JH; Beijnen JH; Steeghs N; Huitema AD
    Ther Drug Monit; 2014 Jun; 36(3):326-34. PubMed ID: 24305627
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical pharmacokinetics and drug-drug interactions of tyrosine-kinase inhibitors in chronic myeloid leukemia: A clinical perspective.
    Cheng F; Wang H; Li W; Zhang Y
    Crit Rev Oncol Hematol; 2024 Mar; 195():104258. PubMed ID: 38307392
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug-drug interactions with tyrosine-kinase inhibitors: a clinical perspective.
    van Leeuwen RW; van Gelder T; Mathijssen RH; Jansman FG
    Lancet Oncol; 2014 Jul; 15(8):e315-26. PubMed ID: 24988935
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bioavailability of tyrosine kinase inhibitors: an added component of assessment.
    Abueg KD
    Clin J Oncol Nurs; 2014 Dec; 18(6):714-6. PubMed ID: 25427707
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of Membrane Drug Transporters on Resistance to Small-Molecule Tyrosine Kinase Inhibitors.
    Neul C; Schaeffeler E; Sparreboom A; Laufer S; Schwab M; Nies AT
    Trends Pharmacol Sci; 2016 Nov; 37(11):904-932. PubMed ID: 27659854
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.